about
sameAs
Phosphate binders for the treatment of chronic kidney disease: role of iron oxyhydroxideInterplay of vitamin D, erythropoiesis, and the renin-angiotensin systemNew insights on the role of vitamin D in the progression of renal damageCorrection of metabolic acidosis improves insulin resistance in chronic kidney diseaseThe burden of nephrotoxic drug prescriptions in patients with chronic kidney disease: a retrospective population-based study in Southern ItalyAutoimmune Thyroiditis and Glomerulopathies.A best practice position statement on pregnancy in chronic kidney disease: the Italian Study Group on Kidney and Pregnancy.Vascular access for hemodialysis: current perspectivesSexual dysfunction in women with diabetic kidneyDiscovery of new risk loci for IgA nephropathy implicates genes involved in immunity against intestinal pathogens.History of L-carnitine: implications for renal disease.Renal amyloidosis in cystic fibrosis: role of colchicine therapy.Association of individual non-steroidal anti-inflammatory drugs and chronic kidney disease: a population-based case control study.Extraskeletal Functions of Vitamin DPrognosis of CKD patients receiving outpatient nephrology care in Italy.Comparative Effectiveness of Biosimilar, Reference Product and Other Erythropoiesis-Stimulating Agents (ESAs) Still Covered by Patent in Chronic Kidney Disease and Cancer Patients: An Italian Population-Based StudyHow Much Are Biosimilars Used in Clinical Practice? A Retrospective Italian Population-Based Study of Erythropoiesis-Stimulating Agents in the Years 2009-2013.Role of Paricalcitol in Modulating the Immune Response in Patients with Renal DiseaseSocio-Economic Factors, Food Habits and Phosphorus Levels in Patients on Hemodialysis.Epidemiology of low-proteinuric chronic kidney disease in renal clinicsVascular erectile dysfunction in chronic renal failure.L-arginine: a new opportunity in the management of clinical derangements in dialysis patients.Emerging drugs for hyperphosphatemia.Thyroid hormone autoantibodies: are they a better marker to detect early thyroid damage in patients with hematologic cancers receiving tyrosine kinase inhibitor or immunoregulatory drug treatments?Salivary phosphate-binding chewing gum reduces hyperphosphatemia in dialysis patients.Skin Involvement and Pulmonary Hypertension Are Associated with Vitamin D Insufficiency in Scleroderma.Vitamin D receptor gene polymorphism and left ventricular hypertrophy in chronic kidney disease.Antiosteoporotic Activity of Genistein Aglycone in Postmenopausal Women: Evidence from a Post-Hoc Analysis of a Multicenter Randomized Controlled Trial.Vitamin D metabolism and activity as well as genetic variants of the vitamin D receptor (VDR) in chronic kidney disease patients.Radioiodine uptake in a renal cyst mimicking a metastasis in a patient affected by differentiated thyroid cancer: case report and review of the literature.New therapeutic strategies under development to halt the progression of renal failure.Vitamin D receptor polymorphism in chronic kidney disease patients with complicated cardiovascular disease.Best practices on pregnancy on dialysis: the Italian Study Group on Kidney and Pregnancy.Monoclonal antibodies for renal diseases: current concepts and ongoing treatments.An overview of experimental and early investigational therapies for the treatment of polycystic kidney disease.Nephro-oncology: a link in evolution.Clinical usefulness of autoantibodies to M-type phospholipase A2 receptor (PLA2R) for monitoring disease activity in idiopathic membranous nephropathy (IMN).Kidney disease and psoriasis: novel evidences beyond old concepts.Kidney-lung connections in acute and chronic diseases: current perspectives.Role of Vitamin D in Vascular Complications and Vascular Access Outcome in Patients with Chronic Kidney Disease.
P50
Q26764806-7331529F-8D49-4A83-99E5-9B3C7B5911C7Q26822500-3BC0743B-FF74-4565-8392-3338421441E1Q26829215-3443D2C3-2E55-45C9-BF4E-8465A601CAB0Q28392247-815A93BF-758F-4537-A989-90A21635E821Q28539876-300B9F79-E858-4563-81CF-8E65A741693DQ33753227-5EE7F637-8187-4F0E-A5CB-644F5AD15ABFQ33844319-FC6881D5-EB21-4564-9EC1-C0B50224EDA8Q33904962-E16FDEB0-482D-42D3-A1A8-9EDF68BF1BE1Q34206413-18A10467-8DAF-4755-A272-E9B59D882793Q34422205-8AAC4FE7-6D41-4D35-8FCE-66225F20F53EQ35058720-38F36F64-2F0B-4EA9-9C0E-C2F26CE38B1DQ35310801-827DBF4E-9CEF-42AF-82A0-829C2364E70BQ35448046-A8240D4B-705D-466F-8AE1-02747CB1A91AQ35640660-FB4B5841-6D4E-4AB2-9601-014C5436B665Q35985791-63408350-C5A6-42B8-A314-185ED279E5C9Q36019803-1113211F-79F4-48A7-AB17-557FCE4BA841Q36034344-FBB9530C-9236-4AD2-94DF-40EA65BD0372Q36103344-D8DBC848-084D-4EFD-B3F2-D155FC12FC15Q36234712-562D7205-A64F-4EFE-B97B-06F185E6DDE9Q36284146-785ECA02-797C-462C-973B-4DF3CEC83A9BQ36368175-CE1EAE69-0E31-4553-A28C-0E0589001C9EQ36529330-2662313D-451B-431B-9444-31FA27BD7C1EQ36944004-4E0C3FFD-9EF1-42C6-92DE-99FD2C0388A0Q36989101-D6F62B48-DAB8-4E75-883E-24CD21800623Q37123248-D1A4C9C3-E28F-47E8-B11D-C62F9AEBE638Q37534843-456E6779-4F97-4B58-99B6-9499E845761BQ37666832-58127A10-0665-4474-8712-C6DBA6280647Q37673312-2E6FE1A6-2B5E-4209-8FCE-7089E88A0B72Q38043393-EB5D54E7-B0A6-41E5-8352-62B6F319D3A3Q38189704-67D94721-F3A9-42DF-A971-847220B9647FQ38201504-E28F3AD9-5036-4C96-A44F-B8A4F5D50092Q38286815-84375AEC-E063-4E89-B508-6FB48AEF5B44Q38475830-EA71B89B-EF0B-4F08-A8C7-4AC94DD29857Q38531349-56369A67-CC71-40AB-B724-A14B5A04BF12Q38540557-4C480BA7-D2CA-43BB-ACE3-9DA9497E0A74Q38554467-60E8A05D-E5BA-428F-844C-2A04D95A5EEDQ38623075-2342FADA-9705-46B9-BAB0-F7307C2D4F52Q38651883-F0A57077-0974-4A2E-9BBE-3FEC3900E40DQ38759694-958DB20D-BFF9-4FA9-98FA-6976B4317561Q38798992-5205C8DA-CDE5-4F31-9CAB-03EFBABCAC22
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Domenico Santoro
@ast
Domenico Santoro
@en
Domenico Santoro
@es
Domenico Santoro
@nl
type
label
Domenico Santoro
@ast
Domenico Santoro
@en
Domenico Santoro
@es
Domenico Santoro
@nl
prefLabel
Domenico Santoro
@ast
Domenico Santoro
@en
Domenico Santoro
@es
Domenico Santoro
@nl
P106
P1153
7006830885
P31
P496
0000-0002-4279-6559